John J. Oppenheimer, MD

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.

Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European Respiratory Society International Congress.

Modified criteria that incorporated symptoms specific to infants and young children increased identification of anaphylaxis in these age groups, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Children experiencing egg-induced anaphylaxis may be seeing certain symptoms that differentiate them from other food-induced anaphylaxis, according to a study published in Annals of Allergy, Asthma and Immunology.

Insect venom was the cause of most cases of occupational anaphylaxis, followed by food, drugs and latex, according to a study published in Allergy.

ANAHEIM, Calif. — “There are a lot of interesting trends,” John J. Oppenheimer, MD, FACAAI, clinical professor at UMDNJ Rutgers, told Healio at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting.

The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 years and older, according to a manufacturer-issued press release.

The severity of previous reactions can predict the potential need for epinephrine treatment during home administration of OIT for food allergy, according to a study published in Annals of Allergy, Asthma & Immunology.

Children who experienced food-induced anaphylaxis at school received epinephrine administered via an autoinjector before going to the hospital more often than those experiencing anaphylaxis at home or at restaurants, data showed.

The costs of epinephrine autoinjectors have decreased since generic options arrived in 2016, but these costs remained high for some patients due to their insurance plans, according to a study.